Evidence map›Paper›PMID 41544678›Full record

ArticleInternational journal of radiation oncology, biology, physics2026

α/β for Hepatocellular Carcinoma Tumors Treated With Radiation Therapy.

Lise Wei, Yaxuan Huang, Randall K Ten Haken, Teodor Stanescu, Laura A Dawson, Theodore S Lawrence, Jeremy M G Taylor

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lise WeiDepartments of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: liswei@umich.edu.
Yaxuan HuangDepartments of Biostatistics, University of Michigan, Ann Arbor, Michigan.
Randall K Ten HakenDepartments of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Teodor StanescuPrincess Margaret Cancer Centre, University of Toronto, Ontario, Canada.
Laura A DawsonPrincess Margaret Cancer Centre, University of Toronto, Ontario, Canada.
Theodore S LawrenceDepartments of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Jeremy M G TaylorDepartments of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Departments of Biostatistics, University of Michigan, Ann Arbor, Michigan.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
TREATMENT VERIFICATION AND TREATMENT PLAN REFINEMENTP01CA059827 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BALTER, JAMES M, LAWRENCE, THEODORE S · 1993 to 2018
$37.9M
NCI NIH HHS P01 CA059827NCI NIH HHS P30 CA046592
6 · The paper itself

Abstract

purposePrimary hepatocellular carcinoma lesions are frequently treated with fractionated radiation therapy. The linear-quadratic (LQ) model can be used to compare different fractionation schemes for their effect on the local recurrence rate of the hepatocellular carcinoma tumors. In this paper, we seek to find the value of the α/β ratio in the LQ model, which gives the best prediction of the recurrence rate. METHODS AND MATERIALS: Two separate data sets were analyzed. The first data set contains the time to recurrence of 390 lesions, treated at 2 institutions between 2008 and 2021. Factors considered were the gross tumor volume (GTV), the fractionation scheme, the dose-volume histogram (DVH) of GTV, and the elapsed time between the first and last dose of radiation. Four different ways of summarizing the DVH, based on the LQ model, were used and combined with the Cox proportional hazards model to estimate the α/β ratio. The second data set contains the recurrence rate at 1, 2, 3, 4, and 5 years, for 46 different fractionation schemes, derived from the results presented in 41 publications, based on a total of 4313 lesions. For this meta-analysis, a linear model of a transformed recurrence rate, assuming an autoregressive covariance structure, was used to estimate the α/β ratio.

resultsFrom the lesion-level data, the best estimate of α/β was in the range 37.5 to 52 Gy, with a wide confidence interval (3.4 to ∞). A combined model of how the radiation was delivered, based on the fraction regimen and elapsed time, was strongly associated with the hazard of recurrence (P < .001). However, the elapsed time alone was not significantly associated with the hazard of recurrence (hazard ratio for a 1 day increase, 1.01; P = .33). The analysis also suggested that larger GTV may lead to a higher hazard of recurrence, but was not statistically significant [hazard ratio of log(GTV) = 1.12, P = .21]. Lower doses in the DVH were better predictors of the outcome than the mean DVH dose. The meta-analysis of the published data gave the best estimate of the α/β ratio of 161.4 Gy, but with a wide confidence interval (4.7 to ∞).

conclusionsBoth analyses suggested a high value of α/β of at least 37.5 Gy, but neither could provide precise estimates, and only very small values could be excluded. From a practical perspective, any value of the α/β ratio of greater than about 20 Gy would give a similar ranking of the merits of different fractionation schemes. To obtain more precise estimates of α/β, the data sets would need to include more patients who received fractionated radiation with doses per fraction in the range of 2.0 to 2.9 Gy.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNeoplasm Recurrence, LocalDose Fractionation, RadiationHumansLinear ModelsProportional Hazards ModelsTime FactorsTumor Burden

Identifiers

PMID41544678
PMCPMC13499972

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.